Home New Customer? Create Account
Member Login:

CMV Enhancer

OG253 - pSF-pA-CMVe-RLuc

PRICE

Starting at: $307.00

Please Choose:

Shipping Option



Enter Quantity:

Full Plasmid Details (PDF)

Sequence (txt)

This plasmid is compatible with all of the other DNA sequences available on this site, which are all sold in the same backbone. This flexibility allows you to create any vector you require, with a variety of functions, simply by compiling the relevant sections from our product range.

Vector: pSF-pA-CMVe-RLuc

Product Code: OG253

Quantity Provided: 5µg

Size (bp): 5259 bp

Bacterial Antibiotic Selection: Kanamycin

Origin and Compatibility: pUC high copy, derived from pBR322   

Copy Number: 500-700 copies per cell

Promoter: Not applicable

Purpose:  This plasmid contains the major immediate early cytomegalovirus (CMV) enhancer region upstream of the Renilla reniformis (RLuc) luciferase reporter. The enhancer can be used to increase the strength of weaker promoters whilst often retaining any regulation that they already have, such as tissue specificity or  transcription factor activation in response to stimulus. This enhancer sequence has been inserted upstream of a synthetic poly-adenylation signal that reduces non-specific transcription of any gene that is inserted into the multiple cloning site.

Poly A signals: If you intend to insert this region into a lentivirus or retrovirus, the polyA signal will reduce the virus titre because of premature genome termination. We also have a variant of this plasmid without the polyA signal that can be used for this purpose if it is required.

Transcription Termination: This plasmid contains three alternative transcription terminators for mammalian, bacterial and bacteriophage (T7) expression. This means that only the promoter needs to be changed to alter the expression system you are using. We sell multiple promoters that can be used in each of these systems. The presence of each terminator does not reduce expression in the alternative systems.

Intellectual Property Status: According to our IP-friendly policy, this plasmid is sold free of reach-through rights on any derivatives you may create.

Quality Sequencing Analysis: This vector has been fully sequenced using primers F1-F10. The sequences and details of these primers are available through our website.

Genetic Modifications to standard parts:

  • CMV enhancer – an NcoI site has been ablated in the CMV enhancer region. This change does not reduce its activity.
  • KanR cassette – This KanR resistance region is not a wild type sequence, it has been modified to remove all restriction sites that conflict with the SnapFast system and to retain a high level of antibiotic resistance. It has been validated in E.coli.
  • Renilla reniformis luciferase – The luciferase gene has been modified to remove NarI, AgeI, SphI, BsgI, StuI, Hind3 sites and two MluI sites to ensure compatibility with all of our products. This gene has also been codon optimised for both prokaryotic and eukaryotic expression.  

Restriction site notes:

  • Bgl2, SwaI and PmeI each cut the vector at two sites positioned to flank the promoter, origin, and KanR, respectively.
  • BsgI and BseRI recognise non-palindromic DNA sequences and cleave upstream of their recognition sites, within the stop codon that is found inside the XbaI restriction site.